Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway
Abstract The introduction of anti-inflammatory therapies has enabled substantial improvement of disease activity in patients with inflammatory bowel diseases (IBD). However, IBD can lead to serious complications such as intestinal fibrosis and colorectal cancer. Therefore, novel therapies reducing t...
Guardado en:
Autores principales: | Kensuke Hachiya, Masahiro Masuya, Naoki Kuroda, Misao Yoneda, Junya Tsuboi, Keiki Nagaharu, Komei Nishimura, Takuya Shiotani, Kohshi Ohishi, Isao Tawara, Naoyuki Katayama |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e58d64e9edc74af080a895f2e1df1344 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Phagocyte Chemoattraction Is Induced through the Mcp-1–Ccr2 Axis during Efferocytosis
por: Sang-Ah Lee, et al.
Publicado: (2021) -
TRPV1 and the MCP-1/CCR2 Axis Modulate Post-UTI Chronic Pain
por: John M. Rosen, et al.
Publicado: (2018) -
The role of MCP-1-CCR2 ligand-receptor axis in chondrocyte degradation and disease progress in knee osteoarthritis
por: Xu,Yuan-kun, et al.
Publicado: (2015) -
Changes of Necroptosis in Irbesartan Medicated Cardioprotection in Diabetic Rats
por: Xu Q, et al.
Publicado: (2021) -
Linkage of CD8+ T cell exhaustion with high-fat diet-induced tumourigenesis
por: Tomonobu Kado, et al.
Publicado: (2019)